☰

Biolitec Holding GmbH & Co KG

Connecting photonics R&D, fiber production and post-market data

Industry
Medical Lasers and Photodynamic Therapy Pharmaceuticals
Headquarters
Vienna, Austria (operations centred in Jena, Germany and Livani, Latvia)
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Biolitec Holding GmbH & Co KG's published strategy and is not endorsed by, or produced in cooperation with, Biolitec Holding GmbH & Co KG. Company website

Strategic priorities

Biolitec develops and sells the LEONARDO family of diode lasers for urology, phlebology, proctology and ENT together with the matching single-use optical fibers that the lasers consume. The LEONARDO Duster lithotripsy system received FDA approval in July 2025, opening the high-volume urology market in the United States and adding a structured post-market surveillance obligation to the company's product line.

The holding company is registered in Vienna, Austria, while the operational centres sit in Jena, Germany for research and commercial activity and in Livani, Latvia at the CeramOptec facility where preforms and finished optical fibers are drawn under one roof. The CeramOptec site has been consolidated since 2014 as the primary production hub, with a secondary site in Selangor, Malaysia supporting the APAC region. Distribution reaches more than ninety country markets through regional hubs in Dubai and elsewhere.

Pharmaceutical activity sits alongside the device business through Biolitec Pharma, which markets Foscan (temoporfin), a photodynamic therapy drug shipped under strict temperature control from Jena and Latvia to clinical end-users. The combined device, consumable and pharmaceutical portfolio makes Biolitec a hybrid device-pharma company whose technical data, regulatory data and supply chain data all live in different parts of the organisation today.

The operational priority that follows from that shape is bringing the data from fiber draw towers, installed laser fleets, regulatory submissions and pharmaceutical cold chain shipments onto a single coherent picture that R&D in Jena, production in Livani, regional sales offices and regulatory affairs can each read.

Challenges we see

  • Digital Integration

    Bridging R&D in Jena and fiber production in Livani

    Fiber draw towers in Livani generate process data covering temperature profiles, draw speed, tension and coating thickness. Research and product engineering sit in Jena, more than 1,200 kilometres away. Translation of new fiber designs into production today depends on manual documentation and travel.

    As the pace of new fiber introductions accelerates, design-for-manufacturing feedback that travels through documents and visits cannot match the iteration speed that the product roadmap implies.

  • Operations Manufacturing

    Reading clinical use from the installed laser fleet

    Each LEONARDO procedure records parameters such as energy, duration, wavelength and the fiber in use. The current generation of devices does not transmit this data back to Biolitec, so clinical use is understood through sales-rep conversations rather than measured.

    Without a data path out of the device, product decisions and commercial offers for the installed base are shaped by anecdote rather than by what the devices have actually been doing.

  • Operations Manufacturing

    Distributing sterile fibers across more than ninety country markets

    Optical fibers are sterile single-use devices with defined shelf lives. Production is concentrated in Livani with secondary capability in Selangor, Malaysia, and the company distributes through regional hubs including Dubai to hospitals in more than ninety countries.

    When demand signals take longer than the supply lead time to surface, the cost of getting the wrong mix of fibers to the wrong region falls on expiration, stockouts and cancelled procedures.

  • Compliance Regulatory

    Sustaining MDR and FDA post-market surveillance at scale

    The July 2025 FDA approval of the LEONARDO Duster adds a structured post-market surveillance obligation. EU MDR Article 83 to 86 expects manufacturers to gather performance and safety data actively and continuously, which the existing paper-survey approach was not designed to support.

    Surveillance inputs that arrive on paper months after a procedure do not let the regulatory file be updated quickly enough to answer the questions that EU MDR and FDA now ask of it.

  • Operations Regulatory

    Maintaining cold chain integrity for Foscan shipments

    Foscan is a photodynamic therapy drug shipped from Jena and Livani to clinical end-users worldwide under Good Distribution Practice. Temperature excursions during transport can render the drug unusable, and the existing monitoring approach relies on records assembled after the fact.

    Where temperature is only confirmed after the shipment, the product has usually already left the chain of custody, which makes a confirmed excursion more a loss event than a preventable one.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Streaming Livani draw-tower process data into Jena R&D

    Engineers in Jena cannot see what is happening inside the Livani draw towers while a production run is in progress. Design-for-manufacturing iteration relies on reports that arrive after the spool is finished, and post-market defect data is correlated manually.

    Connecting draw-tower sensors through OPC UA (Open Platform Communications Unified Architecture) into a secure private cloud lets the Jena team see the same process values the operators see, and lets draw parameters be correlated against post-market fiber performance as a routine data exercise.

    • Biolitec research and development overview, biolitec.com
    • CeramOptec company profile, ceramoptec.com

  2. Reading procedure data back from the LEONARDO fleet

    Each LEONARDO procedure generates a record of energy, duration, wavelength and fiber in use, but the devices do not transmit that record anywhere. Decisions about the next generation of lasers and about commercial offers are based on sales-rep feedback.

    A retrofit data path on the installed fleet, designed to EU data sovereignty expectations, would turn each procedure into an observation point for R&D, service and commercial planning while leaving patient-identifying data on the device side of the boundary.

    • Biolitec LEONARDO laser family product page, biolitec.com
    • FDA approval announcement for LEONARDO Duster, July 2025

  3. Forecasting fiber demand across regional hubs

    Hospitals in more than ninety countries depend on a small set of dedicated fibers for each procedure. Inventory today is managed through historical ordering patterns, with sterility lifespan and regional procedure mix treated as separate judgement calls.

    A demand-and-stock view that joins regional consumption history, procedure mix and sterility expiry dates lets regional hubs replenish against a forecast rather than against a reorder threshold, which reduces both stockout-driven cancelled procedures and expired-stock write-offs.

    • Biolitec worldwide presence, biolitec.com/en/contact/biolitec-worldwide.html
    • Biolitec LEONARDO fiber consumable range product pages, biolitec.com

  4. Running MDR and FDA post-market surveillance as a data system

    Post-market surveillance under EU MDR and FDA today depends on paper-based surgeon surveys and on records assembled by hand. The volume of data expected under the LEONARDO Duster approval will outgrow that approach within a product cycle.

    A mobile-first capture flow keyed to the fiber barcode lets a procedure outcome be recorded at the point of use, with the structured records it produces feeding both regulatory submissions and the R&D evidence base.

    • FDA approval announcement for LEONARDO Duster, July 2025
    • EU Medical Device Regulation 2017/745, Articles 83 to 86

  5. Confirming Foscan cold chain compliance in transit

    Foscan shipments from Jena and Livani to clinical end-users must remain inside their temperature window throughout transport. Today the temperature record is reconstructed from carrier documents and intermittent readings after the shipment is received.

    Continuous temperature logging through the carrier leg, with the resulting record available to the receiving hospital and to Biolitec's quality team, makes an excursion visible at the moment it happens rather than at the moment it is discovered.

    • Biolitec Pharma product information for Foscan (temoporfin)
    • EU Good Distribution Practice guidelines for medicinal products

What we'd propose

  • Digital CDMO

    Connected IT and OT for Livani fiber production

    We connect the Livani fiber draw towers through OPC UA into a secure private cloud, build the digital twin of the production line, and give R&D in Jena and operations in Livani a shared view of the run that is currently in progress.

    • OPC UA connection to the draw towers

      Process data out of the equipment

      Instrument the draw towers so temperature, draw speed, tension and coating thickness leave the equipment in a documented, vendor-neutral form, with the network segmented to IEC 62443 (the international standard for industrial control system security) so the production environment stays isolated from enterprise and external networks.

    • Digital twin of the fiber draw process

      A live model of the run

      Build a live model of the running spool that R&D and production can both watch, with the historical operating envelope behind it so a parameter drift is visible against the prior weeks of runs rather than against an empty chart.

    • Draw-to-defect correlation analytics

      From process data to fiber quality

      Join the process record from the twin to post-market fiber performance and complaint data, so the conditions that lead to a clinical fiber failure are visible inside the engineering team that can act on them.

    • Design-for-manufacturing feedback that previously travelled by report and visit becomes a continuous data loop.
    • The fiber engineering team in Jena sees the same run that operations in Livani is running, with the same numbers.
    • The relationship between draw parameters and clinical performance becomes a measurable property of the production record.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Telemetry and analytics for the LEONARDO installed fleet

    We add a secure data path to the LEONARDO laser fleet so procedure parameters are available to R&D, service and commercial teams, while leaving patient-identifying data on the device side of the regulatory boundary.

    • Secure fleet data acquisition

      Procedure data out of the device

      Add an edge gateway to the installed fleet that records procedure parameters and ships anonymised summaries to a European cloud region, with the device and gateway hardened to IEC 62443 and the data path auditable to EU data sovereignty expectations.

    • Fleet usage analytics

      What the installed base is doing

      Aggregate procedure parameters across the fleet to show power-setting distributions, procedure type mix and regional usage patterns, giving R&D the evidence base it currently lacks and service the planning data it needs to stock parts and visits.

    • Subscription and consumable commercial offers

      Pricing that follows use

      Use the aggregated procedure data to support subscription and pay-per-procedure commercial offers that lower the capital barrier for hospitals while stabilising Biolitec's revenue against the placement cycle.

    • Product and commercial decisions for the installed base rest on measured use rather than on anecdote.
    • Service can plan parts and visits from what the fleet is telling it, rather than from incoming fault reports.
    • New commercial offers become possible because the procedure data exists in a form the commercial team can read.

    We've done this before

    See how we do Enterprise AI
  • Enterprise AI

    Supply chain control tower for fiber distribution

    We build a control tower view across the regional fiber hubs that joins demand history, procedure mix and sterility expiry dates, so replenishment decisions rest on a forecast rather than on a reorder threshold.

    • Demand sensing across regional hubs

      Forecast the next shipment

      Combine regional procedure volumes, historical consumption and procedure-mix data into a rolling demand forecast for each fiber variant, and surface the forecast to the regional commercial and operations leads.

    • Sterility lifecycle tracking

      Expiry as a planning signal

      Track each fiber lot from production through regional hub storage so expiry pressure is visible inside the planning horizon, not after a write-off.

    • Replenishment workflow for hub managers

      Decisions surfaced to the hub

      Present the recommended replenishment for each hub as a single view, with the underlying forecast, on-hand stock and expiry pressure behind it, so the hub manager approves a shipment rather than constructs one.

    • Stockout-driven cancelled procedures are reduced because the next shipment is sized to the next quarter's demand.
    • Sterile expiry write-offs drop because lot rotation is visible before expiry becomes a loss event.
    • Regional hubs operate from the same demand picture instead of from their own historical ordering pattern.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Post-market surveillance platform for EU MDR and FDA

    We build a mobile-first capture flow for procedure outcomes keyed to the fiber barcode, and connect the resulting record to the regulatory submissions file so post-market surveillance becomes a continuous data activity rather than a periodic paperwork exercise.

    • Mobile outcome capture at the point of use

      Surgeon records in under a minute

      Design a capture flow that lets a surgeon scan the fiber barcode and record procedure outcome in under a minute, with the data record carrying the structured fields that EU MDR and FDA expect, not free-form notes that have to be re-interpreted later.

    • Regulatory reporting workflow

      From outcome record to filing

      Assemble the captured records into the post-market surveillance reports that EU MDR and FDA require, with the underlying records retained as the evidence behind each report.

    • RWE analytics feeding back to R&D

      Clinical signal in the engineering room

      Analyse the procedure outcome record for performance patterns and complication signals that point to next-generation fiber and laser design improvements.

    • Surveillance inputs become structured data instead of paper surveys, which lowers the cost of every report and improves its quality.
    • The MDR and FDA regulatory file stays current because the underlying record is current.
    • The data that R&D was missing from clinical use now arrives in a form the engineering team can read.

    We've done this before

    See how we do Digital Lab
  • Agents

    AI agents for regulatory and clinical documentation work

    We deploy narrow, reviewable agents that take the recurring part of regulatory document work: drafting periodic safety update reports and clinical evaluation reports from source records, checking a submission against its template before review, and finding every controlled document a new EU MDR or FDA guidance touches.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a periodic safety update report, a clinical evaluation report or a post-market surveillance summary from the underlying records in the data system, so the regulatory author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its regulatory template and the company's own checklist before it enters the human review queue, returning missing or inconsistent sections with the rest of the document.

    • Change impact search across controlled documents

      Which documents a guidance update touches

      When an EU MDR or FDA guidance document is updated, retrieve every controlled document that references the changed section and rank them by how directly the change applies, so the update scope is established by search rather than by recollection.

    • Review queues move faster because documents arrive complete and already cite their source records.
    • The scope of a guidance change is known on day one rather than after a manual sweep.
    • Every output is traceable to the source records it came from and signed off by a named regulatory reviewer.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Biolitec Holding GmbH & Co KG's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
IT and OT convergence 25 → 75
Livani draw-tower data is held in local logs and is not joined to R&D or post-market records. The IT and OT sides of the business operate against different data estates today.
Connected products 15 → 70
The LEONARDO fleet is offline relative to Biolitec. Service and R&D understand clinical use through sales conversations rather than measured data, and the regulatory file is short on real-world performance evidence.
Supply chain visibility 35 → 80
Distribution across more than ninety country markets is managed against historical ordering patterns. Sterility lifespan and regional demand are tracked separately, and replenishment is reactive rather than forecast-driven.
Regulatory data infrastructure 30 → 85
EU MDR and FDA post-market surveillance is supported by paper surveys and manually assembled reports. The structured capture and reporting that a July 2025 FDA approval will require is not yet in place.
Cross-site collaboration 40 → 85
R&D in Jena, production in Livani and the regional commercial offices work from separate data sources. The design-for-manufacturing loop crosses 1,200 kilometres on documents and visits rather than on a shared data view.
Data sovereignty and security 45 → 90
Cross-border litigation history and EU data sovereignty expectations argue for an EU-resident, on-premise hybrid architecture for fleet data, production data and clinical evidence. The segmentation and audit story behind that posture is still to be built.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Biolitec Holding GmbH & Co KG, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].